Literature DB >> 21709060

Saphenous vein grafts with multiple versus single distal targets in patients undergoing coronary artery bypass surgery: one-year graft failure and five-year outcomes from the Project of Ex-Vivo Vein Graft Engineering via Transfection (PREVENT) IV trial.

Rajendra H Mehta1, T Bruce Ferguson, Renato D Lopes, Gail E Hafley, Michael J Mack, Nicholas T Kouchoukos, C Michael Gibson, Robert A Harrington, Robert M Califf, Eric D Peterson, John H Alexander.   

Abstract

BACKGROUND: Limited information exists on the intermediate-term graft patency and 5-year clinical outcomes of patients receiving saphenous vein grafts with multiple (m-SVG) versus single distal targets (s-SVG) during coronary artery bypass graft (CABG) surgery in the current era. METHODS AND
RESULTS: We studied the association of the use of m-SVG versus s-SVG conduits with 1-year SVG failure (defined as ≥75% angiographic stenosis) and 5-year clinical events (death; death or myocardial infarction [MI]; and death, MI, or revascularization) in 3014 patients undergoing their first CABG surgery enrolled in the Project of Ex-vivo Vein Graft Engineering via Transfection (PREVENT) IV. Of 3014 patients enrolled in PREVENT IV, 1045 (34.7%) had ≥1 m-SVGs during CABG. Vein graft failure at 1-year was higher for m-SVG compared with s-SVG (adjusted odds ratio 1.24, 95% confidence interval 1.03 to 1.48). At 5 years, the adjusted composite of death, MI (including perioperative MI), or revascularization (hazard ratio 1.15, 95% confidence interval 1.00 to 1.31) and death or MI (hazard ratio 1.21, 95% confidence interval 1.03 to 1.43) were significantly higher in patients receiving m-SVGs.
CONCLUSIONS: In patients undergoing first CABG surgery, the use of m-SVG was associated with a higher 1-year vein graft failure rate and trends toward worse clinical outcomes. Additional studies are needed to better understand the most appropriate conduit to improve long-term graft patency and clinical outcomes of patients undergoing CABG surgery. In the meantime, these data should encourage the use of s-SVG over m-SVG when feasible.

Entities:  

Mesh:

Year:  2011        PMID: 21709060      PMCID: PMC5144829          DOI: 10.1161/CIRCULATIONAHA.110.991299

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  20 in total

1.  ACC/AHA 2004 guideline update for coronary artery bypass graft surgery: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1999 Guidelines for Coronary Artery Bypass Graft Surgery).

Authors:  Kim A Eagle; Robert A Guyton; Ravin Davidoff; Fred H Edwards; Gordon A Ewy; Timothy J Gardner; James C Hart; Howard C Herrmann; L David Hillis; Adolph M Hutter; Bruce Whitney Lytle; Robert A Marlow; William C Nugent; Thomas A Orszulak
Journal:  Circulation       Date:  2004-10-05       Impact factor: 29.690

2.  Clinical outcome of single versus sequential grafts in coronary bypass operations at ten years' follow-up.

Authors:  K Meeter; R Veldkamp; J G Tijssen; L L van Herwerden; E Bos
Journal:  J Thorac Cardiovasc Surg       Date:  1991-06       Impact factor: 5.209

3.  Mid-term angiographic comparison of sequential and individual anastomosis techniques for diagonal artery.

Authors:  Bilgehan Savaş Oz; Hikmet Iyem; Hakki Tankut Akay; Cengiz Bolcal; Mehmet Yokusoglu; Erkan Kuralay; Ufuk Demirkilic; Harun Tatar
Journal:  J Card Surg       Date:  2006 Sep-Oct       Impact factor: 1.620

4.  The PRoject of Ex-vivo Vein graft ENgineering via Transfection IV (PREVENT IV) trial: study rationale, design, and baseline patient characteristics.

Authors:  John H Alexander; T Bruce Ferguson; Diane M Joseph; Michael J Mack; Randall K Wolf; C Michael Gibson; Daniel Gennevois; Todd J Lorenz; Robert A Harrington; Eric D Peterson; Kerry L Lee; Robert M Califf; Nicholas T Kouchoukos
Journal:  Am Heart J       Date:  2005-10       Impact factor: 4.749

5.  Sequential vein bypass grafting: tactics and long-term results.

Authors:  J T Christenson; F Simonet; M Schmuziger
Journal:  Cardiovasc Surg       Date:  1998-08

6.  Sequential venous bypass grafts: results 10 years later.

Authors:  J T Christenson; M Schmuziger
Journal:  Ann Thorac Surg       Date:  1997-02       Impact factor: 4.330

7.  Sequential coronary bypass grafts. Long-term follow-up.

Authors:  T M Kieser; G M FitzGibbon; W J Keon
Journal:  J Thorac Cardiovasc Surg       Date:  1986-05       Impact factor: 5.209

8.  Sequential anastomoses in coronary artery grafting: technical aspects and early and late angiographic results.

Authors:  C M Grondin; R Limet
Journal:  Ann Thorac Surg       Date:  1977-01       Impact factor: 4.330

9.  Triple aorto-coronary vein bypass as treatment for coronary insufficiency.

Authors:  R J Flemma; W D Johnson; D Lepley
Journal:  Arch Surg       Date:  1971-07

10.  Technique for the coronary snake graft operation.

Authors:  W H Sewell; K V Sewell
Journal:  Ann Thorac Surg       Date:  1976-07       Impact factor: 4.330

View more
  24 in total

1.  Coronary steal or large collateral? Three cases of graft failure in sequential and composite grafts.

Authors:  Jwalit Morakhia; Padmakumar Ramachandran; Naveen Chandra Ganiga Sanjeeva; Ashok Thakkar
Journal:  BMJ Case Rep       Date:  2014-11-12

2.  Long term outcomes of radial artery grafting in patients undergoing coronary artery bypass surgery.

Authors:  James Tatoulis; Thomas A Schwann
Journal:  Ann Cardiothorac Surg       Date:  2018-09

3.  Surgery: Less is more for CABG conduits.

Authors:  Christoph A Schmitt
Journal:  Nat Rev Cardiol       Date:  2011-08-02       Impact factor: 32.419

4.  Saphenous vein graft failure after coronary artery bypass surgery: insights from PREVENT IV.

Authors:  Connie N Hess; Renato D Lopes; C Michael Gibson; Rebecca Hager; Daniel M Wojdyla; Brian R Englum; Michael J Mack; Robert M Califf; Nicholas T Kouchoukos; Eric D Peterson; John H Alexander
Journal:  Circulation       Date:  2014-09-26       Impact factor: 29.690

5.  Autologous tissue patches acquire vascular identity depending on the environment.

Authors:  Hualong Bai; Jianming Guo; Shirley Liu; Xiangjiang Guo; Haidi Hu; Tun Wang; Toshihiko Isaji; Shun Ono; Bogdan Yatsula; Ying Xing; Alan Dardik
Journal:  Vasc Investig Ther       Date:  2018-07-10

6.  Hybrid coronary revascularization for the treatment of multivessel coronary artery disease.

Authors:  Michael O Kayatta; Michael E Halkos; John D Puskas
Journal:  Ann Cardiothorac Surg       Date:  2018-07

7.  Efficient gene transfer and durable transgene expression in grafted rabbit veins.

Authors:  Liang Du; Jingwan Zhang; Alexander W Clowes; David A Dichek
Journal:  Hum Gene Ther       Date:  2015-01       Impact factor: 5.695

8.  Impact of statins and beta-blocker therapy on mortality after coronary artery bypass graft surgery.

Authors:  Femi Philip; Eugene Blackstone; Samir R Kapadia
Journal:  Cardiovasc Diagn Ther       Date:  2015-02

9.  TGF-β signaling mediates endothelial-to-mesenchymal transition (EndMT) during vein graft remodeling.

Authors:  Brian C Cooley; Jose Nevado; Jason Mellad; Dan Yang; Cynthia St Hilaire; Alejandra Negro; Fang Fang; Guibin Chen; Hong San; Avram D Walts; Robin L Schwartzbeck; Brandi Taylor; Jan D Lanzer; Andrew Wragg; Abdalla Elagha; Leilani E Beltran; Colin Berry; Robert Feil; Renu Virmani; Elena Ladich; Jason C Kovacic; Manfred Boehm
Journal:  Sci Transl Med       Date:  2014-03-12       Impact factor: 17.956

10.  Sex differences in outcomes after coronary artery bypass grafting: a pooled analysis of individual patient data.

Authors:  Mario Gaudino; Antonino Di Franco; John H Alexander; Faisal Bakaeen; Natalia Egorova; Paul Kurlansky; Andreas Boening; Joanna Chikwe; Michelle Demetres; Philip J Devereaux; Anno Diegeler; Arnaldo Dimagli; Marcus Flather; Irbaz Hameed; Andre Lamy; Jennifer S Lawton; Wilko Reents; N Bryce Robinson; Katia Audisio; Mohamed Rahouma; Patrick W Serruys; Hironori Hara; David P Taggart; Leonard N Girardi; Stephen E Fremes; Umberto Benedetto
Journal:  Eur Heart J       Date:  2021-12-28       Impact factor: 29.983

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.